ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease

Abstract Triple-negative breast cancer (TNBC) patients with residual disease (RD) after neoadjuvant systemic therapy (NAST) are at high risk for recurrence. Biomarkers to risk-stratify patients with RD could help individualize adjuvant therapy and inform future adjuvant therapy trials. We aim to inv...

Full description

Bibliographic Details
Main Authors: Shane R. Stecklein, Bruce F. Kimler, Rachel Yoder, Kelsey Schwensen, Joshua M. Staley, Qamar J. Khan, Anne P. O’Dea, Lauren E. Nye, Manana Elia, Jaimie Heldstab, Trisha Home, Stephen Hyter, Kamilla Isakova, Harsh B. Pathak, Andrew K. Godwin, Priyanka Sharma
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00512-7

Similar Items

Similar Items